ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ALT Altimmune Inc

6.90
1.73 (33.46%)
After Hours
Last Updated: 19:53:47
Delayed by 15 minutes

Period:

Draw Mode:

Volume 55,037,721
Bid Price 6.90
Ask Price 6.96
News -
Day High 7.615

Low
2.09

52 Week Range

High
17.17

Day Low 5.53
Company Name Stock Ticker Symbol Market Type
Altimmune Inc ALT NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.73 33.46% 6.90 19:53:47
Open Price Low Price High Price Close Price Prev Close
5.71 5.53 7.615 6.88 5.17
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
211,422 55,037,721 $ 6.78 $ 373,125,874 - 2.09 - 17.17
Last Trade Time Type Quantity Stock Price Currency
19:53:48 5 $ 6.9597 USD

Altimmune (ALT) Options Flow Summary

Overall Flow

Bullish

Net Premium

364k

Calls / Puts

600.00%

Buys / Sells

122.22%

OTM / ITM

23.53%

Sweeps Ratio

0.19%

Altimmune Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
370.19M 53.73M - -68k -84.71M -1.58 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Altimmune News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ALT Message Board. Create One! See More Posts on ALT Message Board See More Message Board Posts

Historical ALT Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.117.6153.084.0435,956,8813.79121.86%
1 Month2.697.6152.3153.9110,410,5504.21156.51%
3 Months2.647.6152.093.644,194,3914.26161.36%
6 Months4.277.6152.093.582,814,6242.6361.59%
1 Year10.9017.172.095.492,304,976-4.00-36.7%
3 Years12.2924.612.099.511,747,978-5.39-43.86%
5 Years3.1735.101.4510.031,630,1383.73117.67%

Altimmune Description

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV).

Your Recent History

Delayed Upgrade Clock